07 January, 2015. Biotecnol presents results of its pan-cancer Tribody™ programme Tb535.The product has shown a remarkable efficacy both in-vitro and in-vivo, in Malignant Mesothelioma, an untreatable and highly-aggressive cancer which is caused by past occupational exposure to asbestos. It’s estimated to affect about 30 cases per million people in Australia, USA, Belgium, and Great Britain and is worryingly rising in countries like Russia, India, Japan, Brazil and China due to the continuous production of Asbestos in these countries.
Tb535 is a bispecific antibody based on its proprietary Tribody™ format, combining binding to the pan-carcinoma marker, 5T4 oncofetal antigen also known asWnt-Activated Inhibitory Factor 1, which is completely absent from normal tissue, and a monovalent CD3 binder which activates T-cells only when accumulated at cancer cells. Preclinical studies indicated efficient tumour cell-killing on a variety of tumour types, including Pleural Malignant Mesothelioma, Triple Negative Breast Cancer and KRAS mutated Colorectal Cancer.
In-vivo studies in subcutaneous and orthotopic models of Malignant Mesothelioma have shown that low-doses Tb535 has a remarkable efficacy in killing the tumours and prolonging survival of the animals. Also, preclinical work indicated a high-degree of tolerability and absence of off-target and even on-target toxicity, especially regarding cytokine release.Biotecnol used its Trisoma™ technology platform to generate a highly-stable Tb535 product candidate which will be now be entering in clinical development work in 2015. Biotecnol will continue developing the product and is actively seeking for territorial partners for co-developing and co-marketing the product in selected indications.
Biotecnol will be presenting updated results at the Biotech Showcase, on Tuesday the 13th January 2015 at 1.45 PM, which takes place during the next J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, CA 12-15 of Jan 2015.
About the Tribody™ format
Tribody™ molecules are multi-specific antibodies, produced by established recombinant DNA technology methods, which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional functionality can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binding sites and can combine different functions, such as the ability to engage and redirect potent immune-effector cells like T-cells or NK-cells whilst retaining the ability to target more than one epitope in a tumour target, or more than one target in the same tumour, all in one single molecule.
Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.Back to news